Share Price and Basic Stock Data
Last Updated: January 23, 2026, 5:44 pm
| PEG Ratio | 4.82 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
3B Blackbio DX Ltd operates in the agrochemicals and pesticides sector, with a current market capitalization of ₹1,395 Cr. The company reported a price of ₹1,625 per share, with a price-to-earnings (P/E) ratio of 28.4. The company has shown fluctuating sales trends over recent quarters, with total sales recorded at ₹17 Cr in September 2022, declining to ₹14 Cr in June 2023, before rebounding to ₹19 Cr in September 2023. The trailing twelve months (TTM) revenue stood at ₹104 Cr, reflecting a growth trajectory with projected sales for FY 2025 expected to reach ₹96 Cr. The company has effectively leveraged its operational capabilities, with operating profit margins (OPM) averaging around 43% across the recent quarters, indicating strong pricing power and cost management in a competitive market. Furthermore, the company has consistently maintained a positive operating profit, which stood at ₹50 Cr for FY 2025, showcasing its ability to generate earnings from core operations despite market volatility.
Profitability and Efficiency Metrics
3B Blackbio DX Ltd has demonstrated robust profitability metrics, with a net profit of ₹49 Cr and a return on equity (ROE) of 19.4%. The company’s net profit margin stood impressively at 49.43% for FY 2025, highlighting its ability to convert revenue into substantial profit efficiently. The operating profit margin (OPM) has fluctuated but remained strong, peaking at 67.57% for FY 2025. The interest coverage ratio (ICR) is exceptionally high at 600.85x, indicating that the company has no borrowings and thus faces minimal risk from interest obligations. Additionally, the return on capital employed (ROCE) rose to 26% for FY 2025, reflecting effective utilization of capital resources. However, the cash conversion cycle (CCC) of 235 days poses a potential risk, as it indicates longer durations for converting inventory and receivables into cash, which could affect liquidity if not managed efficiently.
Balance Sheet Strength and Financial Ratios
3B Blackbio DX Ltd’s balance sheet reflects solid financial health, characterized by zero borrowings and total reserves of ₹290 Cr as of September 2025. The company’s current and quick ratios stand at 7.11x and 6.64x, respectively, indicating a strong liquidity position and the ability to meet short-term obligations without reliance on debt. The price-to-book value (P/BV) ratio is recorded at 5.16x, suggesting that the market values the company significantly above its book value, typically reflecting investor confidence in future growth prospects. The company’s asset turnover ratio of 0.35 indicates moderate efficiency in utilizing assets to generate revenue. With total liabilities of ₹341 Cr, the financial structure appears robust, although the rising total liabilities trend warrants monitoring to ensure it does not outpace growth in assets and equity.
Shareholding Pattern and Investor Confidence
The shareholding pattern of 3B Blackbio DX Ltd reveals a diversified ownership structure, with promoters holding 41.28% of the shares, which indicates a significant level of control and commitment to the company. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 2.64% and 1.82% of the shares, respectively, reflecting limited institutional interest compared to the public’s stake of 54.26%. The number of shareholders has decreased from 13,798 in December 2022 to 10,709 by September 2025, which may suggest a consolidation phase or potential investor fatigue. Despite this, the stability in promoter holding and the relatively high public shareholding could be seen as a positive indicator for long-term investor confidence. However, the low institutional ownership might indicate a need for enhanced investor relations to attract larger institutional players.
Outlook, Risks, and Final Insight
3B Blackbio DX Ltd presents a mixed outlook with significant strengths and underlying risks. On one hand, its strong profitability metrics, zero debt, and high liquidity position suggest a resilient operational framework capable of weathering market fluctuations. The company’s ability to maintain high operating profit margins and net profit margins is commendable and positions it favorably against its peers. On the other hand, the lengthy cash conversion cycle and declining number of shareholders could pose challenges, indicating potential liquidity issues and waning investor interest. Moving forward, the company could benefit from strategies to enhance operational efficiency and investor engagement. Should it successfully address these risks while capitalizing on its strengths, 3B Blackbio DX Ltd may continue to thrive in the competitive agrochemical landscape, potentially attracting greater institutional investment and expanding its market share.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,597 Cr. | 1,066 | 2,114/1,056 | 11.4 | 487 | 0.56 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 769 Cr. | 228 | 391/165 | 15.8 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 58.3 Cr. | 112 | 149/56.6 | 10.4 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,653 Cr. | 205 | 331/198 | 100 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 787 Cr. | 22.2 | 36.9/16.3 | 61.5 | 22.8 | 0.90 % | 12.9 % | 9.95 % | 1.00 |
| Industry Average | 10,301.05 Cr | 1,038.40 | 28.96 | 369.04 | 0.46% | 15.21% | 19.87% | 6.67 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 15 | 18 | 14 | 19 | 18 | 23 | 19 | 29 | 25 | 22 | 22 | 34 |
| Expenses | 8 | 7 | 11 | 8 | 11 | 9 | 13 | 8 | 13 | 10 | 15 | 10 | 19 |
| Operating Profit | 9 | 7 | 7 | 6 | 8 | 9 | 10 | 11 | 16 | 15 | 8 | 12 | 15 |
| OPM % | 53% | 50% | 41% | 45% | 41% | 50% | 43% | 56% | 55% | 59% | 35% | 53% | 43% |
| Other Income | 2 | 3 | 1 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | 11 | 10 | 8 | 9 | 10 | 11 | 14 | 14 | 19 | 18 | 13 | 16 | 20 |
| Tax % | 23% | 22% | 38% | 22% | 26% | 24% | 36% | 21% | 23% | 24% | 36% | 20% | 23% |
| Net Profit | 8 | 8 | 5 | 7 | 8 | 9 | 9 | 11 | 15 | 13 | 8 | 13 | 15 |
| EPS in Rs | 11.20 | 8.96 | 7.72 | 9.71 | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 |
Last Updated: December 28, 2025, 11:32 am
Below is a detailed analysis of the quarterly data for 3B Blackbio DX Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Jun 2025) to 34.00 Cr., marking an increase of 12.00 Cr..
- For Expenses, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 9.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 15.00 Cr., marking an increase of 3.00 Cr..
- For OPM %, as of Sep 2025, the value is 43.00%. The value appears to be declining and may need further review. It has decreased from 53.00% (Jun 2025) to 43.00%, marking a decrease of 10.00%.
- For Other Income, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Jun 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 4.00 Cr..
- For Tax %, as of Sep 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from 20.00% (Jun 2025) to 23.00%, marking an increase of 3.00%.
- For Net Profit, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Jun 2025) to 15.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 17.14. The value appears strong and on an upward trend. It has increased from 14.67 (Jun 2025) to 17.14, marking an increase of 2.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:22 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 104 |
| Expenses | 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 54 |
| Operating Profit | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 50 |
| OPM % | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 48% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 18 |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 66 |
| Tax % | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | |
| Net Profit | 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 49 |
| EPS in Rs | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 57.21 |
| Dividend Payout % | 0% | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 66.67% | 60.00% | 1325.00% | -71.93% | -18.75% | 23.08% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -6.67% | 1265.00% | -1396.93% | 53.18% | 41.83% | 26.92% |
3B Blackbio DX Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 27% |
| 3 Years: | 6% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 44% |
| 3 Years: | 14% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 32% |
| 3 Years: | 57% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 30% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:15 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 290 |
| Borrowings | 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 0 |
| Other Liabilities | 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 42 |
| Total Liabilities | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 341 |
| Fixed Assets | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 17 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | 160 |
| Other Assets | 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 163 |
| Total Assets | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 341 |
Below is a detailed analysis of the balance sheet data for 3B Blackbio DX Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 290.00 Cr.. The value appears strong and on an upward trend. It has increased from 260.00 Cr. (Mar 2025) to 290.00 Cr., marking an increase of 30.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 42.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 27.00 Cr. (Mar 2025) to 42.00 Cr., marking an increase of 15.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 341.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 296.00 Cr. (Mar 2025) to 341.00 Cr., marking an increase of 45.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 156.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 4.00 Cr..
- For Other Assets, as of Sep 2025, the value is 163.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 31.00 Cr..
- For Total Assets, as of Sep 2025, the value is 341.00 Cr.. The value appears strong and on an upward trend. It has increased from 296.00 Cr. (Mar 2025) to 341.00 Cr., marking an increase of 45.00 Cr..
Notably, the Reserves (290.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -6.00 | -7.00 | -6.00 | -6.00 | -1.00 | 1.00 | 5.00 | 148.00 | 34.00 | 27.00 | 32.00 | 50.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 |
| Inventory Days | 120 | 145 | 143 | 175 | 164 | 141 | 124 | |||||
| Days Payable | 189 | 218 | 203 | 186 | 69 | 66 | 28 | |||||
| Cash Conversion Cycle | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 |
| Working Capital Days | 144 | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 |
| ROCE % | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 55.57 | 37.40 | 34.55 | 43.40 | 151.66 |
| Diluted EPS (Rs.) | 55.57 | 37.40 | 34.55 | 43.40 | 151.66 |
| Cash EPS (Rs.) | 56.93 | 38.70 | 35.77 | 43.88 | 152.82 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 313.27 | 263.15 | 261.50 | 229.69 | 197.92 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 313.27 | 263.15 | 261.50 | 229.69 | 197.92 |
| Revenue From Operations / Share (Rs.) | 112.59 | 86.51 | 82.54 | 107.65 | 302.66 |
| PBDIT / Share (Rs.) | 76.08 | 53.12 | 48.55 | 58.73 | 204.07 |
| PBIT / Share (Rs.) | 74.82 | 51.88 | 47.40 | 57.84 | 203.25 |
| PBT / Share (Rs.) | 74.69 | 51.74 | 47.13 | 57.69 | 202.94 |
| Net Profit / Share (Rs.) | 55.66 | 37.46 | 34.62 | 42.98 | 152.00 |
| NP After MI And SOA / Share (Rs.) | 55.66 | 37.46 | 34.62 | 42.98 | 152.00 |
| PBDIT Margin (%) | 67.57 | 61.40 | 58.81 | 54.56 | 67.42 |
| PBIT Margin (%) | 66.45 | 59.97 | 57.42 | 53.72 | 67.15 |
| PBT Margin (%) | 66.34 | 59.80 | 57.10 | 53.59 | 67.05 |
| Net Profit Margin (%) | 49.43 | 43.30 | 41.94 | 39.92 | 50.21 |
| NP After MI And SOA Margin (%) | 49.43 | 43.30 | 41.94 | 39.92 | 50.21 |
| Return on Networth / Equity (%) | 17.76 | 14.39 | 15.14 | 21.04 | 86.23 |
| Return on Capital Employeed (%) | 23.13 | 19.28 | 17.76 | 24.73 | 101.13 |
| Return On Assets (%) | 16.12 | 12.93 | 12.11 | 16.76 | 58.83 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 0.35 | 0.32 | 0.30 | 0.13 | 0.38 |
| Current Ratio (X) | 7.11 | 7.04 | 8.05 | 4.82 | 2.76 |
| Quick Ratio (X) | 6.64 | 6.56 | 7.49 | 4.38 | 2.64 |
| Inventory Turnover Ratio (X) | 11.24 | 2.41 | 2.33 | 2.66 | 2.68 |
| Interest Coverage Ratio (X) | 600.85 | 365.87 | 183.32 | 413.58 | 669.53 |
| Interest Coverage Ratio (Post Tax) (X) | 440.55 | 259.05 | 131.73 | 303.65 | 499.68 |
| Enterprise Value (Cr.) | 1319.35 | 600.55 | 278.94 | 248.35 | 196.43 |
| EV / Net Operating Revenue (X) | 13.68 | 8.10 | 4.51 | 3.08 | 0.86 |
| EV / EBITDA (X) | 20.24 | 13.19 | 7.67 | 5.64 | 1.28 |
| MarketCap / Net Operating Revenue (X) | 14.36 | 8.90 | 5.04 | 3.17 | 0.94 |
| Price / BV (X) | 5.16 | 2.96 | 1.82 | 1.67 | 1.62 |
| Price / Net Operating Revenue (X) | 14.36 | 8.90 | 5.04 | 3.17 | 0.94 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.12 | 0.53 |
After reviewing the key financial ratios for 3B Blackbio DX Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.57, marking an increase of 18.17.
- For Diluted EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.57, marking an increase of 18.17.
- For Cash EPS (Rs.), as of Mar 25, the value is 56.93. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 56.93, marking an increase of 18.23.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 112.59. It has increased from 86.51 (Mar 24) to 112.59, marking an increase of 26.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 76.08. This value is within the healthy range. It has increased from 53.12 (Mar 24) to 76.08, marking an increase of 22.96.
- For PBIT / Share (Rs.), as of Mar 25, the value is 74.82. This value is within the healthy range. It has increased from 51.88 (Mar 24) to 74.82, marking an increase of 22.94.
- For PBT / Share (Rs.), as of Mar 25, the value is 74.69. This value is within the healthy range. It has increased from 51.74 (Mar 24) to 74.69, marking an increase of 22.95.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
- For PBDIT Margin (%), as of Mar 25, the value is 67.57. This value is within the healthy range. It has increased from 61.40 (Mar 24) to 67.57, marking an increase of 6.17.
- For PBIT Margin (%), as of Mar 25, the value is 66.45. This value exceeds the healthy maximum of 20. It has increased from 59.97 (Mar 24) to 66.45, marking an increase of 6.48.
- For PBT Margin (%), as of Mar 25, the value is 66.34. This value is within the healthy range. It has increased from 59.80 (Mar 24) to 66.34, marking an increase of 6.54.
- For Net Profit Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 10. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 20. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.76. This value is within the healthy range. It has increased from 14.39 (Mar 24) to 17.76, marking an increase of 3.37.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.13. This value is within the healthy range. It has increased from 19.28 (Mar 24) to 23.13, marking an increase of 3.85.
- For Return On Assets (%), as of Mar 25, the value is 16.12. This value is within the healthy range. It has increased from 12.93 (Mar 24) to 16.12, marking an increase of 3.19.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.35. It has increased from 0.32 (Mar 24) to 0.35, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 7.11. This value exceeds the healthy maximum of 3. It has increased from 7.04 (Mar 24) to 7.11, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 6.64. This value exceeds the healthy maximum of 2. It has increased from 6.56 (Mar 24) to 6.64, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.24. This value exceeds the healthy maximum of 8. It has increased from 2.41 (Mar 24) to 11.24, marking an increase of 8.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 600.85. This value is within the healthy range. It has increased from 365.87 (Mar 24) to 600.85, marking an increase of 234.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 440.55. This value is within the healthy range. It has increased from 259.05 (Mar 24) to 440.55, marking an increase of 181.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,319.35. It has increased from 600.55 (Mar 24) to 1,319.35, marking an increase of 718.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.68. This value exceeds the healthy maximum of 3. It has increased from 8.10 (Mar 24) to 13.68, marking an increase of 5.58.
- For EV / EBITDA (X), as of Mar 25, the value is 20.24. This value exceeds the healthy maximum of 15. It has increased from 13.19 (Mar 24) to 20.24, marking an increase of 7.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 2.96 (Mar 24) to 5.16, marking an increase of 2.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in 3B Blackbio DX Ltd:
- Net Profit Margin: 49.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.13% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.76% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 440.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 6.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.6 (Industry average Stock P/E: 28.96)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 49.43%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | 7-C, Industrial Area, Bhopal Madhya Pradesh 462023 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dhirendra Dubey | Chairman & Managing Director |
| Mr. N K Dubey | Whole Time Director |
| Mr. Harihar Prasad Thapak | Independent Director |
| Mr. Abdul Moin Khan | Independent Director |
| Mrs. Mithala Dubey | Director |
| Mr. Vivek Saihgal | Additional Director |
FAQ
What is the intrinsic value of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd's intrinsic value (as of 24 January 2026) is ₹1635.50 which is 0.09% lower the current market price of ₹1,637.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,405 Cr. market cap, FY2025-2026 high/low of ₹2,100/1,151, reserves of ₹290 Cr, and liabilities of ₹341 Cr.
What is the Market Cap of 3B Blackbio DX Ltd?
The Market Cap of 3B Blackbio DX Ltd is 1,405 Cr..
What is the current Stock Price of 3B Blackbio DX Ltd as on 24 January 2026?
The current stock price of 3B Blackbio DX Ltd as on 24 January 2026 is ₹1,637.
What is the High / Low of 3B Blackbio DX Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of 3B Blackbio DX Ltd stocks is ₹2,100/1,151.
What is the Stock P/E of 3B Blackbio DX Ltd?
The Stock P/E of 3B Blackbio DX Ltd is 28.6.
What is the Book Value of 3B Blackbio DX Ltd?
The Book Value of 3B Blackbio DX Ltd is 347.
What is the Dividend Yield of 3B Blackbio DX Ltd?
The Dividend Yield of 3B Blackbio DX Ltd is 0.24 %.
What is the ROCE of 3B Blackbio DX Ltd?
The ROCE of 3B Blackbio DX Ltd is 25.8 %.
What is the ROE of 3B Blackbio DX Ltd?
The ROE of 3B Blackbio DX Ltd is 19.4 %.
What is the Face Value of 3B Blackbio DX Ltd?
The Face Value of 3B Blackbio DX Ltd is 10.0.